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Zusammenfassung
Hintergrund: Durch isolierte Elektroden übertragene
elektrische Felder mit niedriger Intensität und sorgfältig
abgestimmter mittlerer Frequenz (tumor-treating fields,
TTFelder) können das Wachstum von Tumorzellen selek-
tiv verhindern. Patienten und Methoden: Diese offene,
prospektive Pilotstudie sollte die Sicherheit, Verträglich-
keit und Wirksamkeit der TTFelder-Behandlung verab-
reicht durch das NovoTTF-100A™-Gerät bei Patienten
mit lokal fortgeschrittenen und/oder metastasierten soli-
den Tumoren evaluieren. Alle 6 Patienten waren intensiv
vorbehandelt; es stand keine Standardtherapie mehr für
sie zur Verfügung. TTFelder wurden mindestens 14 Tage
als Dauertherapie verabreicht. Ergebnisse: Es wurden
keine behandlungsbedingten schwerwiegenden Neben-
wirkungen dokumentiert. Eine partielle Remission einer
Hautläsion eines Mammakarzinoms wurde beobachtet;
bei 3 Patienten wurde eine Stabilisierung und bei einer
Patientin ein Fortschreiten der Erkrankung unter Thera-
pie beobachtet. Schlussfolgerung: Trotz der geringen
 Patientenzahl in der vorliegenden Studie sind die Absenz
von Toxizität und die Hinweise auf eine gute Wirksamkeit
vielversprechend und erfordern größere klinische Stu -
dien mit dieser neuen Therapieoption.
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Summary
Background: The transmission of electric fields using
 insulated electrodes has demonstrated that very low-in-
tensity, properly tuned, intermediate-frequency electric
fields, termed tumor-treating fields (TTFields), selectively
stunts tumor cell growth and is accompanied by a de-
crease in tumor angiogenesis. Patients and Methods:
This open, prospective pilot study was designed to
 evaluate the safety, tolerability, and efficacy profile of
TTFields treatment in patients with locally advanced
and/or metastatic solid tumors using the NovoTTF-
100A™ device. All 6 patients were heavily pre-treated
with several lines of therapy; no additional standard
treatment option was available to them. TTFields treat-
ment using continuous NovoTTF-100A lasted a mini-
mum of 14 days and was very well tolerated. Results: No
related serious adverse events occurred. Outcomes
showed 1 partial response of a treated skin metastasis
from a primary breast cancer, 3 cases where tumor
growth was arrested during treatment, and 1 case of dis-
ease progression. One mesothelioma patient experi-
enced lesion regression near TTFields with simultaneous
tumor stability or progression in distal areas. Conclusion:
Although the number of patients in this study is small,
the lack of therapy toxicity and the efficacy observed in
data gathered to date indicate the potential of TTFields
as a new treatment modality for solid tumors, definitely
warranting further investigation. 
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Introduction
In the laboratory setting and in clinical practice, alternating
electric fields show a wide range of effects on living tissues.
At very low frequencies (below 1 kHz), alternating electric
fields stimulate excitable tissues, such as nerve, muscle, and
heart, through membrane depolarization [1]. The transmis-
sion of such fields by radiation is insignificant, and, therefore,
they are usually applied directly by contact electrodes, though
some  applications have also used insulated electrodes. At
very high frequencies (above many MHz), a completely dif-
ferent biological effect is observed. Tissue heating becomes
dominant primarily due to dielectric losses [2]. This phenom-
enon serves as the basis for some commonly used medical
treatment modalities, including diathermy and radio-frequency
tumor ablation, which can be applied through insulated elec-
trodes [3].
It was recently demonstrated that very low-intensity, properly
tuned, intermediate-frequency electric fields, termed tumor-
treating fields (TTFields), selectively stunt the growth of
tumor cells [4]. This inhibitory effect was demonstrated in nu-
merous proliferating cell types, while non-proliferating cells
and tissues were unaffected. Interestingly, Nordenström’s [5]
1989 observation that different cell types show specific inten-
sity and frequency dependencies when intraneoplastic anodic
and cathodic fields were used, is again confirmed with
TTFields inhibition. At the cellular level, the TTFields effect
was shown to be due to arrest of proliferation and selective
destruction of dividing cells. The damage caused by the fields
to the replicating cells was dependent on the orientation of
the mitotic spindle in relation to the field vectors, indicating
that this effect is non-thermal. Indeed, temperature measure-
ments made within culture dishes during treatment and on the
skin above treated tumors in vivo, showed no significant ele-
vation in temperature compared to control cultures/mice. At
the subcellular level, it was found that TTFields disrupt the
normal polymerization-depolymerization process of micro-
tubules during mitosis, similar to what has been seen in cells
treated with agents that interfere directly or indirectly with
microtubule polymerization (e.g. paclitaxel or docetaxel)
[6–10]. Animal studies have confirmed the described inhibi-
tion of tumor growth following less than 1 week of TTFields
treatment [4]. The growth inhibition was accompanied by a
decrease in angiogenesis within the tumor, due to inhibition of
endothelial cell proliferation, while no treatment-related side
effects were observed.
Our group is the first to treat patients worldwide with this new
therapeutic modality. This open, prospective pilot study was
designed to evaluate the safety and tolerability profile of
TTFields treatment and the tumor response in patients with
locally advanced and/or metastatic solid tumors. A medical
device specifically designed to apply intermittent electric
fields through insulated electrodes was built into adhesive
strips which were then fixed onto the patient’s skin. The
NovoTTF-100A™ instrument was developed by Novocure
Ltd., Haifa, Israeli.
Patients and Methods
Prior to study commencement, the trial protocol was approved by the
local Ethics Committee, and concurrence with the required standards of
the Declaration of Helsinki was ensured. Patients with histologically-
proven, locally advanced or metastatic malignant tumors were recruited.
Major selection criteria were: age ≥ 18 years, at least 1 measurable lesion,
tumor location accessible to field application through externally placed
electrodes, ECOG performance ≤ 2, no additional standard therapy avail-
able, and no concomitant anti-tumor therapy.
Six patients, with a median age of 66 years (range 24–76) and suffering
from various cancers, were recruited, and provided written informed con-
sent. All patients were previously treated with several lines of therapy,
and no additional standard treatment option was available to them. Four
of the patients suffered from skin lesions, 1 had a glioblastoma multiforme
(GBM), and 1 had metastases from a mesothelioma in the retroperitoneal
cavity (table 1). Therapy was initiated in the outpatient clinic of the Basel
University Hospital under medical supervision for the first 6 hours of
treatment. Thereafter, patients were released to continue treatment on an
ambulatory basis. Safety and tolerability parameters were determined. 
The NovoTTF-100A device used in this trial (depicted in figs. 1 and 2) is a
portable, battery-operated device that produces TTFields. These TTFields
are applied to the patient by means of surface electrodes that are electri-
cally insulated, thereby ensuring that resistively coupled electric currents
are not delivered to the patient. The electrodes are placed on the patient’s
shaved skin over a layer of adhesive hydrogel, and held in place with hy-
poallergenic adhesive strips. The gel beneath the electrodes must be re-
placed every 3–4 days, and the skin re-shaved in order to maintain optimal
coupling between the electrodes and the skin. All treatment parameters
are pre-set so there are no electrical output adjustments available to, or
required by, the patient. Patients received continuous TTFields treatment
at 100–200 kHz at a field intensity of 0.7 V/cm root mean square (RMS).
TTFields were applied to 2 pairs of insulated electrode arrays in an alter-
nating fashion at 1 s per pair. Each electrode had a surface area of
4.5–13.5 cm2. The 2 pairs were arranged normal to each other so as to gen-
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Patient, # Date of initial diagnosis Primary tumor Location of treated lesion
1 22/05/1998 invasive ductal breast cancer right chest wall, axillary skin lesions
2 08/11/2002 malignant melanoma left thigh, skin lesions
3 31/03/2003 pleural mesothelioma regional spread to retroperitoneum
4 23/10/2000 adenocarcinoma of the breast left chest wall, skin lesion
5 05/09/2002 glioblastoma multiforme left hemisphere of brain
6 18/02/2003 invasive ductal breast cancer left chest wall, skin lesion
Table 1. Demo-
graphics
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erate sequentially 2 perpendicular fields in the tumor positioned in be-
tween them [4, 11]. The first 2 patients recruited received 2 weeks of
 continuous TTFields therapy. From patient 3 onwards, all patients
 received at least 4 weeks of continuous treatment. Patients were allowed
to disconnect from the device for up to 30 min, twice a day.
Results
Safety
The total exposure time of the 6 patients to TTFields treat-
ment was 128 full days. Individual patients were exposed to
NovoTTF-100A treatment for 13–46 days. The TTFields treat-
ment was generally well tolerated, and the compliance was 
> 80%. Time without treatment was due to battery changes,
electrode gel replacement, and time taken by the patient for
personal needs (e.g. bathing). The patients learned rapidly to
manage normal daily life with the NovoTTF100A. The only
improvement most patients suggested was that the device
should become lighter and less noisy. Adverse events were
mild for all patients. The only adverse event related to treat-
ment was a grade 1 skin irritation, with reddening of the skin
in 3 out of 6 patients. These lesions occurred beneath the elec-
trodes, and were reversible. Treatment of the skin lesions
 included the repositioning of the electrodes and topical appli-
cation of steroid-containing ointments. No related abnormal
laboratory values or serious adverse events were recorded. 
Efficacy
All patients suffered from progressive disease prior to enter-
ing the study, and all were intensively pre-treated. Tumor size
was assessed by digital photography in the 4 patients with skin
tumors as the measurable lesion, and the other 2 patients by
computed tomography (CT) scans. One partial response of a
treated skin metastasis of a primary breast cancer was ob-
served (fig. 3). In 3 patients, an arrest of tumor growth during
treatment was seen (fig. 4), and 1 patient experienced progres-
sive disease. In the mesothelioma patient (Patient 3), some
tumor regression was seen in the area of the tumor which was
exposed to TTFields, while the other portions of the tumor
were stable or progressive. Patient 5 with rapidly growing
GBM resistant to temozolomide and carmustine, likewise did
not respond to the 4 weeks of treatment with TTFields. On
the basis of the treatment data subsequently obtained on
GBM patients, we can possibly attribute this failure to the
treatment duration being too short [4].
Discussion
TTFields are a new cancer treatment modality that has shown
a favorable tolerability and efficacy profile in preclinical
 studies. We report the results of the first study with TTFields
in humans, and confirm, in the clinical setting, the feasibility 
364 Onkologie 2008;31:362–365 Salzberg/Kirson/Palti/Rochlitz
Fig. 1. Picture of
NovoTTF portable
device.
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Fig. 3. Patient with a 51% reduction in tumor size after 4 weeks of
TTFields treatment (partial response).
 
Fig. 4. Patient with flattening of the tumor after treatment and the
 appearance of healthy looking granulation tissue at the tumor margins. 20%
reduction in tumor size after 6 weeks of TTFields treatment (stable disease).
 
Fig. 2. Treatment
setting with NovoTTF
for malignant
glioblastoma. Picture
shows attached elec-
trodes.
Baseline
After NovoTTF treatment 
(4 weeks)
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of the TTFields treatment with the NovoTTF device. Other
 subsequently conducted studies confirm these findings [4].
Furthermore, patients experienced very low toxicity as a con-
sequence of this treatment, which can be explained in light of
the known passive electric properties of normal tissues within
the body and the effects of electric fields applied via insulated
electrodes. More specifically, 2 types of toxicities may be ex-
pected in an electric field-based treatment modality. First, the
fields could interfere with the normal function of excitable tis-
sues within the body causing, in extreme cases, cardiac ar-
rhythmias and seizures. However, this is not truly a concern
with TTFields since, as frequencies increase above 1 kHz, exci-
tation by alternating sinusoidal electric fields decreases dra-
matically due to the parallel resistor-capacitor nature of the
cell membrane which has a time constant of about 1 ms. Sec-
ondly, the anti-mitotic effect of TTFields might be expected to
damage the replication of rapidly dividing healthy cells within
the body (bone marrow, small intestine mucosa). The lack of
damage to intestinal mucosa in animals undergoing TTFields
treatment is probably a reflection of the fact that the small
 intestine mucosal cells have a slower replication cycle than
neoplastic cells, and that the fraction of the field that affects
the mucosal areas where the cells replicate is small due to
 bypassing lower resistance pathways. Bone marrow is almost
completely naturally protected from TTFields due to its high
electric resistance from both the surrounding bone and bone
marrow itself, relative to other tissues in the body. 
TTFields therapy was very well tolerated and safe. The 4
patients with skin lesions showed transient yet convincing in-
hibition in the growth rate of the treated lesions. One of these
patients had a partial response to treatment. Although the
number of patients in this study is small, the lack of toxicity of
this therapy and the promise of efficacy seen in the data gath-
ered to date indicate the potential of TTFields as a new treat-
ment modality for solid tumors, definitely warranting further
investigation in larger clinical trials.
Onkologie 2008;31:362–365NovoTTF in Solid Tumors 365
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